Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Elanco Animal Health's Q4 Earnings Beat Expectation, FY22 Sales Guidance Trail Estimates

Elanco Animal Health Inc (NYSE:ELAN) has reported Q4 EPS of $0.21 higher than $0.12 reported a year ago, surpassing analysts' view of $0.17.

  • Revenue was $1.11 billion, a decrease of 2% YY, unfavorably impacted by approximately $60 million of previously disclosed items that benefited Q4 FY20., beating the consensus of $1.10 billion.
  • Pet Health's revenue decreased 1% and was flat when excluding the unfavorable impact from foreign exchange rates. 
  • Price growth across the portfolio and volume growth was more than offset by the impact of competitive pressure on older generation parasiticides.
  • Farm Animal revenue decreased 1% and was flat, excluding foreign exchange rates' unfavorable impact. 
  • The gross margin improved from 47.7% to 54%, with 500 basis points attributable to the negative impact of the amortization of inventory fair value adjustments recorded from the acquisition of Bayer Animal Health in Q4 FY20.
  • Guidance: Elanco expects FY22 revenue of $4.75 billion - $4.8 billion versus the analyst consensus of $4.86 billion.
  • It expects adjusted EPS of $1.18 - $1.24 (consensus of $1.22) and adjusted EBITDA of $1.14 billion - $1.18 billion.
  • For Q1 FY22, the company forecasts revenue of $1.2 billion - $1.23 billion versus the analyst consensus of $1.25 billion.
  • It expects adjusted EPS of $0.33 - $0.38 (consensus of $0.37) and adjusted EBITDA of $310 million - $340 million.
  • Price Action: ELAN shares closed lower by 0.89% at $25.75 on Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.